Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00358215 · ClinicalTrials.gov registry record · Phase 3
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
A Phase 3 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,278
- Enrollment target
NCT00358215 is a Phase 3 study that has completed, run by Amgen. The registered enrollment target is 2,278 participants.
The verdict
NCT00358215, a Phase 3 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,278 participants
- Enrollment target
Study Summary
The purpose of the study is to determine the efficacy of treatment of anemia with darbepoetin alfa compared to placebo on the composite of time to death from any cause or first hospital admission for worsening heart failure in patients with symptomatic left ventricular systolic dysfunction and anemia.
Interventions
- DRUG Placebo
- DRUG Darbepoetin alfa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,278 participants |
| Start Date | 2006-06-01 |
| Est. Completion | 2012-10-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00358215
The ClinicalTrials.gov registry entry for NCT00358215 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 2,278 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00358215 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00358215 about?
NCT00358215 is a clinical study titled "RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial". The purpose of the study is to determine the efficacy of treatment of anemia with darbepoetin alfa compared to placebo on the composite of time to death from any cause or first hospital admission for worsening heart failure in patients with symptomatic left ventricular systolic dysfunction and anemi...
What is the current status of trial NCT00358215?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,278 participants. The study started on 2006-06-01. Estimated completion is 2012-10-11.
What interventions are being tested in trial NCT00358215?
The interventions under investigation include: Placebo (DRUG), Darbepoetin alfa (DRUG).
Who is sponsoring clinical trial NCT00358215?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.